Preliminary diagnostic performance of the VIDAS® TB-IGRA for the detection of Mycobacterium tuberculosis infection and disease
Serge Diagbouga,Arthur D. Djibougou,Camille Pease,Ariana Alcaide,Audrey Berthoux,Natalie Bruiners,Daniela Maria Cirillo,Ardjouma Combary,Nadine Falchero,Deborah Handler,Antoinette Kabore,Alfred Lardizabal,Amanda Lopes,Marissa Loubet,Philippe Manivet,Clemence Margain,Valerie Meunier,Faiza Mougari,Alberta Onyuka,Sophie Rivoiron,Tani Sagna,Mathilde Sanvert,Leon Sawadogo,Jacques Simpore,Emmanuelle Cambau,Maria Laura Gennaro
DOI: https://doi.org/10.1101/2022.04.01.22271763
2024-10-15
Abstract:Importance: Accurate diagnosis of tuberculosis (TB) infection can be achieved with interferon gamma ; release assays. Their performance can be improved by utilizing fully automated, single–patient formats.
Objective: Establish clinical thresholds for a new interferon gamma; release assay, the VIDAS® TB–IGRA, and compare diagnostic performance in detecting tuberculosis infection and disease with the established QuantiFERON–TB Gold Plus (QFT–Plus).
Design: Preliminary diagnostic performance study (October 2nd, 2019 to February 20th, 2020).
Setting: Multicenter.
Participants: Participants were divided into TB disease, high–risk, and low–risk populations. The confirmed TB disease population included 107 patients. The high–risk population included 162 individuals with flagged risk factors on a questionnaire but without objective clinical confirmation of TB. The Low–risk population included 117 healthy blood donors from the French National Blood Bank.
Exposures: Tuberculosis.
Main Outcomes and Measures: Positive and negative percent agreement (PPA, NPA) were determined between the VIDAS® TB–IGRA and QFT–Plus. In the TB disease and low–risk populations, sensitivity was also measured against bacterial culture and PCR.
Results: The VIDAS® TB–IGRA produced fewer indeterminate results than the QFT–Plus (1/107 vs. 23/107) in the TB disease population. One analysis included indeterminate results as false negatives (94 positives and 10 false negatives vs. 56 positives and 48 false negatives), and the VIDAS® TB–IGRA exhibited higher sensitivity than the QFT–Plus (90.4% vs. 53.8%) (p<0.0001). Another analysis excluded indeterminate results (76 positives and 4 false negatives vs. 55 positives and 25 false negatives), and the VIDAS® TB–IGRA again exhibited higher sensitivity than the QFT–Plus (95.0% vs. 68.8%) (p<0.0001). A 98.2% PPA was calculated between the two tests with this dataset.
In the high–risk population, the VIDAS® TB–IGRA exhibited a strong PPA (94.4%) with the QFT–Plus. However, a lower than expected NPA was observed (85.2%). In the low–risk population, the VIDAS® TB–IGRA demonstrated high specificity (94.9%) and a strong NPA (98.2%) with the QFT–Plus.
Conclusions and Relevance: The fully automated VIDAS® TB–IGRA is a promising diagnostic test for both TB infection and disease. It exhibits higher sensitivity while maintaining specificity and produces fewer indeterminate interpretations. Its easy–to–use, single–patient format may lead to increased TB testing to help with the worldwide eradication of the disease.